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Aim: The aim of the present study is to address a genome-wide search for novel 
methylation biomarkers in the rectal cancer (RC), as only scarce information on 
methylation profile is available. Materials & methods: We analyzed methylation status 
in 25 pairs of RC and adjacent healthy mucosa using the Illumina Human Methylation 
450 BeadChip. Results: We found significantly aberrant methylation in 33 genes. 
After validation of our results by pyrosequencing, we found a good agreement with 
our findings. The BPIL3 and HBBP1 genes resulted hypomethylated in RC, whereas 
TIFPI2, ADHFE1, FLI1 and TLX1 were hypermethylated. An external validation by 
TCGA datasets confirmed the results. Conclusion: Our study, with external validation, 
has demonstrated the feasibility of using specific methylated DNA signatures for 
developing biomarkers in RC.
First draft submitted: 20 April 2016; Accepted for publication: 28 June 2016; Published 
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Background
Colorectal cancer (CRC) is the third most 
common cause of cancer and the second lead-
ing cause of cancer death in Europe and the 
USA [1]. From a clinical point of view, malig-
nancies in the colon (CC) and the rectum 
(RC, comprising approximately 33%) rep-
resent two distinct entities that require dif-
ferent treatment strategies. The distinction 
between the CC and RC is largely anatomi-
cal but it impacts both surgical and radio-
therapeutic management with often different 
prognoses [2]. In contrast with CC, which 
has a low incidence of local recurrence and 
longer survival time, patients with RC have a 
higher incidence of recurrence requiring the 
addition of pelvic radiation therapy (chemo-
radiation) [3,4]. As a consequence, the clini-
cal management of patients with RC differs 
significantly from that of the CC in terms of 
surgical technique, the more frequent use of 
radiotherapy and method of chemotherapy 
administration [5].
There are some examples of studies that 
tried to clarify whether established CRC risk 
factors may or may not be risk factors for CC 
or RC separately [6]. For example, physical 
inactivity and body mass index have been 
associated with CC cancer but not with rec-
tal cancer [7]. However, for RC only, very lim-
ited data are available, since existing studies 
usually failed to separate these entities.
From a molecular point of view, the preva-
lence of K-ras mutations and mutation pat-
terns in the TP53 gene in RC differs from 
those seen in CC [8]. For all these reasons, 
RC and CC should preferably be analyzed 
separately to reduce the attenuation of risk 
estimates for RC in the studies.
At present, it is generally assumed that CRC 
arises as a consequence of an accumulation 
of genetic and epigenetic alterations, which 
transforms colonic epithelial cells into adeno-
carcinoma cells. DNA methylation is an epi-
genetic event that alters gene expression and 
that may lead to cancer and other human dis-
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eases. Global DNA hypomethylation is a type of altered 
DNA methylation which often occurs in repetitive ele-
ments of the genome such as long interspersed repeat 
sequences (LINE-1). Global DNA hypomethylation is 
associated with genomic instability and chromosome 
abnormalities [9,10]. Gene-specific methylation occurs 
at specific regions of the gene such as gene promoters 
and can either silence or activate the gene. It is gener-
ally accepted dogma that CpG island hypermethylation 
leads to transcriptional gene silencing [11].
The epigenetic changes associated with CRC, espe-
cially aberrant CpG island methylation in the pro-
moter regions of tumor suppressor genes, have been 
tested in several studies [2]. In general, up to 10% of 
CpG islands in cancer epigenomes may be aberrantly 
methylated, which can lead to the silencing of thou-
sands of gene promoters in the average cancer [12]. 
Moreover, CRC-associated aberrant methylation is 
not exclusively limited to CpG islands but may com-
prise ‘CpG island shores’ or areas that are less dense 
in CpG dinucleotides within 2 kb upstream of a CpG 
island [13,14]. Methylation of the CpG island shores may 
also be associated with the transcriptional inactivation 
and expression of splice variants [15].
In the last decade, technologies for analyses on 
genome scale have progressed, and new tools have 
been implemented to characterize the full spectrum 
of molecular heterogeneity in many types of cancer 
cells [16]. With respect to CRC, genome-wide meth-
ylation changes have been identified in the past few 
years [13,15,17].
To our knowledge, no published studies focused on 
epigenetic diversity in RC by using a state-of-the-art 
high-density methylation array. In the present study, 
CpG-level methylation of tumor and matched adjacent 
tissues from RC patients were analyzed using Infinium 
HumanMethylation450K BeadChips. This enabled 
us to characterize differentially methylated regions 
involved in RC pathogenesis and identify novel can-




The study comprised 64 paired samples (tumor tissue 
and adjacent nonmalignant rectal mucosa [ANMRM]) 
from 32 patients with RC. We included only those 
patients that at the time of the collection, did not 
receive any adjuvant therapy yet. Clinical character-
istics of patients are presented in Table 1. The Ethics 
committees of the Institute for Clinical and Experi-
mental Medicine, the Thomayer Hospital, Prague (C.j. 
786/09(G0-04-09), the General University Hospital, 
Prague (C.j. 12/11 Grant GAČR 1.LF UK) and the 
Teaching Hospital and Medical School, Pilsen (for 
project IGA MZCR NT14329) approved the study. 
All patients signed informed consent. The Ethical 
Review Board, Uppsala, Sweden approved the Swedish 
participation in the study.
DNA methylation array
The 64 RC and ANMRM specimens were homoge-
nized by MagNA Lyser (Hoffmann-La Roche, Prague, 
Czech Republic) and the genomic DNA was extracted 
using the AllPrep DNA/RNA Isolation Kit (Qiagen, 
Prague, Czech Republic) protocol according to the 
manufacturer’s instructions. DNA samples were ana-
lyzed with the Illumina Infinium HumanMethyl-
ation450K BeadChip according to standard laboratory 
procedures obtained from Illumina, described in details 
by Sandoval et al. [18]. The BeadChips were read by an 
iScan scanner and the data collection was performed in 
the GenomeStudio software (version 1.0).
Data processing
CpG sites with bead count less than three in more than 
5% of the samples were removed, together with sites 
where more than 1% of the samples had a detection 
Table 1. Patient’s clinical characteristics.







CIN status:  
– MSS 32
– MSI 0




TNM stage:  
– Stage I 8
– Stage II 10
– Stage III 8
– Stage IV 6
Therapy:  
– Neoadjuvant therapy 5
– Adjuvant therapy 9
CIN: Chromosomal instability; MSI: Microsatellite instable; MSS: Microsatellite stable. 
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p-value > 0.05 were filtered away from the raw data. 
The data were quantile normalized before the calcula-
tion of β-values. Beta mixture quantile dilation was 
used to eliminate the probe type bias in the Illumina 
Infinium technology. The combination of Quantile 
normalization together with beta mixture quantile 
dilation was recently suggested as the most effective 
normalization strategy when dealing with Illumina 
HumanMethylation450 BeadChip data [17]. Genetic 
variations may affect probe hybridization; therefore, 
probe filtering for single nucleotide polymorphisms 
was applied according to the Supplementary Table 1 
from Nordlund et al. [19]. After filtering, 434,749 CpG 
sites remained for further analysis. Probes on X and Y 
chromosomes were removed prior to calculating the 
Δβ values. The gene body regional analysis included 
all the CpG sites annotated to the same RefSeq gene 
(within the boundaries of 5′ and 3′ UTRs) and a new 
averaged β-value was calculated. When a CpG site 
was annotated to more than one gene, it was used in 
the average calculation for all present genes. A CpG 
locus was considered differentially methylated if 
the Δβ-value (between tumor and ANMRM tissue 
samples) ≥ |0.3| and the adjusted p-value < 0.05. A 
cut-off value of |0.2| represents the detection limit of 
differential methylation with 99% CI [20].
Array validation with pyrosequencing
Six CpG sites targeted by the array were validated 
using the Pyrosequencing assay technology. CpG sites 
of interest were located on TIFPI2, HBBP1, ADHFE1, 
BPIL3, FLI1 and TLX1 genes, and 12 sample pairs pre-
viously analyzed with the Illumina Infinium Human-
Methylation450K BeadChip were analyzed for valida-
tion. Five hundred nanograms of DNA were used for 
the bisulfite treatment using the EZ DNA Methylation 
Gold kit according to the instructions and eluted in 
14 μl elution buffer (Zymo Research, Freiburg, Ger-
many). PCR and sequencing primers were designed 
using Pyromark assay design software 2.0 (Qiagen). 
Fifty microliter PCR reaction was performed with 
the HotStarTaq DNA Polymerase Kit (Qiagen), con-
taining 0.15 μmol/l of each primer, 1.25 units of Taq 
polymerase, 1.5–2.5 mM MgCl
2
 and 0.1 mM each of 
dGTP, dATP, dTTP, dCTP and approximately 40 ng 
of bisulfite-treated DNA was added as a template. The 
PCR primers, annealing temperatures and amplicon 
sizes are shown in Supplementary Table 1. All prim-
ers were purchased from [21]. The PCR program was 
as follows: initial denaturation step of 5 min at 95°C, 
followed by 50 cycles of 45-s denaturation at 94°C, 
45 s of annealing at 54 or 56°C with an extension of 
45 s at 72°C and one cycle for 7 min at 72°C. After 
PCR, the samples were prepared for pyrosequencing 
using the Vacuum Prep Workstation (Qiagen): 37 μl 
of the amplicon, 3 μl Streptavidin Sepharose HP Beads 
(Amersham Biosciences, UK) and 40 μl binding buffer 
(10 mmol/l Tris-HCl, 2 mol/l NaCl, 1 mmol/l EDTA, 
0.1% Tween-20, Milli-Q (18.2 MΩ × cm) water, pH 
7.6) were mixed and used in the Vacuum Prep work-
station. The biotinylated amplicons were immobilized 
onto the Streptavidin sepharose beads and then passed 
through one denaturation and two washing steps 
using the Vacuum Prep Workstation according to a 
standard protocol. The amplicons were subsequently 
transferred to a plate containing sequencing primers 
(0.4 μmol/l) in 40 μl annealing buffer (20 mmol/l 
Tris-Acetate, 2 mmol/l Magnesium acetate, pH 7.6). 
Sequencing was performed using a Pyromark Gold 
Q96 Reagent Kit and a PSQ 96ID system (Qiagen). 
The nucleotide addition order was optimized by the 
Pyro Q-CpG software version 1.0.9 (Qiagen). Results 
were automatically analyzed using the same software.
External validation in TCGA rectal tumor 
& normal samples
Results from methylation profiling on RC patients 
were compared with an open access dataset of RC indi-
viduals from the cancer genome atlas (TCGA) proj-
ect. Level 3 genomic data from RC publicly available 
in TCGA were employed as validation test set. TCGA 
DNA methylation data were generated using the Illu-
mina Infinium Meth450K platform and presented as 
β values, with 0 indicating 0% DNA methylation and 
β values of 1 indicating 100% DNA methylation [2]. 
Methylation data on 485,577 CpG sites from 98 rec-
tal tumors and seven ANMRM rectal tissue samples 
were obtained from the TCGA Data Portal. To vali-
date our results, we also investigated RNA expression 
data for RC patients (RNAseq. Level 2 data available 
at the time of manuscript preparation) by the Wan-
derer tool [22], an interactive viewer to explore DNA 
methylation and gene expression data in TCGA. This 
set comprises 91 RC patients and nine ANMRM. 
The overlap of tissues for methylation and expres-
sion data was the following: 89 RC patients and two 
ANMRM. The unadjusted p-values < 0.05 were con-
sidered as statistically significant, since these analyses 
were hypothesis driven.
Gene functional classification
We used the functional annotation tool available in 
the Database for Annotation, Visualization and Inte-
grated Discovery to identify the gene ontology (GO) 
terms that were over-represented in the list of hyper- 
and hypomethylated genes. To narrow the number of 
genes in the list, we selected genes with differentially 
methylated CpG sites in the 5′UTR and upstream 
1196 Epigenomics (2016) 8(9) future science group
Research Article    Vymetalkova, Vodicka, Pardini et al. 
gene region: in total, 806 hypermethylated genes and 
302 hypomethylated genes were included.
Statistical analysis
All statistical analyses on data measured with the DNA 
methylation array were performed using the R-package 
environment [23]. Color balance adjustment and back-
ground correction were performed using the methylumi 
package available from the Bioconductor project [24]. 
Filtering was performed using the ‘pfilter’ function with 
default settings from the R-package wateRmelon, also 
available from the Bioconductor project. The data were 
quantile normalized, using the ‘nanet’ method from the 
same R-package, prior to calculating the p-values for dif-
ference in DNA methylation using the empirical Bayes’ 
moderated t-statistic [25].
The Benjamini–Hochberg method was used to adjust 
the p-values for multiple testing [26]. A simple t-test was 
used for TCGA 3 level methylation data.
Results
Data preprocessing
We have analyzed 64 tissue samples using the Illumina 
Methylation array (485,577 CpG sites investigated). Two 
samples failed to meet the criteria of the probe call rate 
and were excluded from further analysis along with their 
paired specimen. Due to the preoperative radiotherapy, 
rectal tumors may contain fairly variable number of 
cancer cells. For this reason, we initially performed a 
paired chromosomal analysis displaying DNA methyla-
tion changes Δβ ≥ |0.3| and excluded the sample pairs 5, 
11, 12, 18 and 29 with no changes in DNA methylation 
of this magnitude, Supplementary Figure 1. The inclu-
sion of patients with Δβ ≤ |0.3| is in fact only likely to 
dilute the solid findings, not adding new, extra findings 
to the results. The exclusion of five sample pairs (<10% 
of patients) with Δβ-value ≤ |0.3| was, therefore, manda-
tory according to the design. In total, seven sample pairs 
were removed.
Differentially methylated genes
In the principal component analysis based on the dif-
ferential DNA methylation of the CpG loci there was a 
marked separation among RC and ANMRM (Figure 1). 
Applying the criterion Δβ ≥ 0.3, we found 5929 CpG 
sites differentially methylated in RC with the majority 
of them (4350) located within a gene (Figure 2A & B). Of 
these last, 3527 were hypermethylated and 823 hypo-
methylated. These CpG sites mapped to 1192 differ-
ent genes, mostly on chromosomes 1, 4, 6–8 and 13 
(Figure 2A & B). Hypermethylation was predominantly 
observed in CpG islands. On the other hand, hypometh-
ylation was predominantly found in intergenic regions, 
so called open sea (Figure 2C & D). We used Database 
for Annotation, Visualization and Integrated Discovery 
to identify GO terms enriched in our list of differen-
tially methylated genes. The hypomethylated genes were 
involved in processes such as receptor and membrane 
activity and the hypermethylated genes in multicellular 
organism development, neurogenesis or regulation of 
cellular processes (Table 2).
When performing an unguided gene regional analysis 
(including CpG sites from 5′ and 3′UTRs), we found 
33 genes differentially methylated in RC. The specimens 
were divided into two clusters representing on the left, 
the ANMRM tissues and on the right, the RC (Figure 3): 
only two patients, RC9 and RC10 were misclassified.
We identified those genes with the highest quan-
titative differences in methylation between RC and 
ANMRM. The unguided analysis was based primar-
ily on the analyzed Δβ-values and CpG sites with an 
adjusted p-value < 0.05. The differential methylation for 
the top ten hypo- and hypermethylated CpG sites and 
genes ranged between -0.47 and -0.53, and from 0.55 to 
0.62, respectively (Table 3). The majority of these CpG 
sites were located within gene body regions. Particu-
larly, the most hypermethylated CpG sites in ADHFE1, 
TFPI2 and FLI1 genes exhibited a large number of sig-
nificantly aberrantly methylated CpG sites in cancer tis-
sue: 19 CpG sites out of 23 analyzed covering ADHFE1 
gene; 23 out of 25 covering TFPI2 and 39 out of 47 in 
FLI1. RC tissues displayed significant hypermethylation 
in the upstream of the 5′ region of ADHFE1 (Figure 4) 
while hypomethylation was found in the gene body. Sev-
eral CpG sites in this gene (cg01588438, cg20912169, 
cg09383816 and cg20040765) pointed to regions with 
considerable difference between tumor and healthy 
tissues (Δβ fractions of -0.26 and 0.57–0.62).
RC tissues also displayed significant CpGs hyper-
methylation in the 5′upstream region of the FLI1 gene; 
in contrast CpG sites belonging to the so called S_Shore 
displayed hypomethylation (from cg01681098 till the 
end of the gene; Figure 4).
Other genes with a similar switch pattern were 
ZNF804B and ZNF793, whereas ZNF385B or RASSF2 
showed the opposite direction of the switch (Figure 4).
The 3′UTR region of GPR85 in RC tissues showed 
a significant hypomethylation while the gene body and 
5′UTR region had significant hypermethylation. Inter-
estingly, the region 1500kb upstream of a transcription 
start site (TSS) again showed hypomethylation of RC 
(Figure 4).
Validation of the methylation array data by 
pyrosequencing
The differential methylation of six selected genes 
was validated by pyrosequencing in a subset of tis-
sues already analyzed with the Illumina BeadChip 
www.futuremedicine.com 1197
Figure 1.  Principal component analysis composed of CpG sites after filtering for cancer. The tumor tissue (red) 
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arrays. Results were in agreement with the array data 
(Supplementary Figure 2). RC tissues displayed signifi-
cant hypomethylation in the BPIL3 and HBBP1 genes, 
whereas in TIFPI2, ADHFE1, FLI1 and TLX1 tumors 
resulted as hypermethylated.
External validation of the DNA methylation 
& mRNA expression
The most hypo- and hyper-methylated CpGs identified 
in our study, as well as 33 genes differentially methyl-
ated from the unguided hierarchical clustering analy-
sis (see heatmap, Figure 3) were investigated also in the 
TCGA datasets (98 rectal tumors and seven ANMRM 
rectal tissue) as an external validation. There was a 
good agreement in differences in DNA methylation 
between RC and ANMRM tissues among our and the 
TCGA datasets (Table 3 & Supplementary Table 2).
For RNA-seq, the TCGA dataset available on Wan-
derer tool were for 91 rectal tumors and nine ANMRM 
rectal tissues. When we overlapped methylation data 
and RNA-seq in Wanderer, the data in common were 
only for 89 rectal cancers and two ANMRM tissues.
Generally, the genes with hypermethylated CpG 
sites evinced lower expression levels in tumors 
when compared with their ANMRM (particularly 
ADHFE1, FLI1, NPY and ITGA4). Higher mRNA 
levels in tumors were observed for PRKAR1B, SND1 
and TFPI2. For the genes with hypomethylated CpG 
sites, only CYP27A1 showed increased expression lev-
els. On the other side, decreased expression levels were 
observed for ITGBL1 and MYBPC3 genes. The major-
ity of these CpG sites were localized in the gene body 
or 5′UTR region, none of them were located in the 
promoter region of genes.
For those genes observed differentially methylated 
in the heat map, a general lower expression of all tested 
genes was observed in RC tissues when compared 
with their ANMRM counterparts (from p = 0.02 
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Figure 2.  Genomic distribution of differentially methylated regions (see facing page). (A) Regional distribution 
of differentially methylated CpG sites in rectal cancer patients. (B) Chromosomal distribution of differentially 
methylated CpG sites in rectal cancer patients. (C) The distribution of the hypermethylated and hypomethylated 
CpG sites over seven gene categories: TSS1500, TSS200, 5′UTR, first exon, gene body, 3′UTR and intergenic regions. 
(D) The distribution of the hypermethylated and hypomethylated CpG sites over CpG islands, shores, shelves 
and open sea regions. For categorization, the CpG counts were normalized by the number of CpGs in the same 
category represented on the 450K array. The percentage of normalized CpG counts is indicated in the bars.
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to p < 10-7). The only exception was for the TLX1 
gene, where significantly higher expression levels were 
observed in RC in comparison to ANMRM (p < 10-6; 
Supplementary Figure 3). Particularly in the gene body 
region of TLX1, tumor hypermethylation was noticed 
in our study.
Using the TCGA database, we searched for corre-
lations between methylation and RNA-seq expression 
data for the most hypo- and hyper-methylated CpGs 
identified in our study. RNA-seq expression data were 
available for a subset of RC patients in the TCGA proj-
ect (89 tumor tissues and two ANMRM). Because of 
this limited number of ANMRM in TCGA dataset, 
we were not able to investigate whether changes in 
DNA methylation observed by us were correlated with 
respective transcript levels.
Discussion
The design of the present study was guided by the 
insight of the different histological and molecular 
features among CC and RC tissues [28]. We focused 
on RC, which has in general been under-represented 
in epigenetic CRC studies. In the present study, RC 
tissues were characterized by differential methylation 
of a limited subset of genes showing altered methyla-
tion throughout all regions of the gene. In addition, 
the absolute values of the differences (Δβ) were quite 
large, usually >0.50. These two features highlight that 
this limited set of genes constitutes a strong epigenetic 
signature for RC.
From the epidemiological and therapeutic point of 
view, CC and rectal tumors are considered as differ-
ent entities [4]. They are functionally different and 
exposed to fecal matter for different time laps. RC, in 
particular, is exposed to stool in a more concentrated 
and direct way compared with CC. Also, as undigested 
matters pass through the CC, they are coated with 
alkaline mucus. The different levels of pH in proxi-
mal and distal locations may influence susceptibility 
to environmental factors [29]. In addition, the peculiar 
microenvironment of the RC could have modulatory 
effects on tumor behavior in addition to promoter 
methylation and could also obscure any methylation 
differences [30].
The recently published data from the TCGA project 
suggested that the overall patterns of changes in meth-
ylation, mRNA and miRNA are indistinguishable 
between CC and RC [2]. Methylation data obtained 
from the clinical rectal paired samples studied in the 
present work may be adequate for use in comparative 
analyses in other RC methylation studies. The differ-
ent epigenetic landscapes between adjacent nonmalig-
nant mucosal tissues from the right CC, the left CC 
and the RC may contribute to determining which 
genes will show up with the largest Δβ when compar-
ing the tumor and the ANMRM tissues from these 
different locations. It is the delta value, not the absolute 
one in the tumor tissues that determine which genes 
are players in the cancer process.
In our study, we found common RC-specific meth-
ylation patterns consisting of 5929 CpGs that were sig-
nificantly different from those of their healthy counter-
parts. These CpG sites mapped 1192 different genes, 
mostly at chromosomes 1, 4, 6–8 and 13. GO and 
pathway analysis showed a significant enrichment of 
the genes containing hypermethylated CpG sites that 
were related to developmental and regulation activities 
such as regulation of metabolic or biosynthetic pro-
cesses, of transcription or gene expression. By contrast, 
the hypomethylated CpG sites were related to signal 
transduction and receptor activity, suggesting that 
quite diverse cellular processes may be influenced by 
methylation events and participate in the development 
of pathological processes in RC.
There is scarce information on the role of the pro-
posed gene signature in RC pathogenesis. The TCGA 
portal presents only few healthy tissues available 
for RC. The present study reports for the first time 
an equal representation of the tumor tissue and its 
healthy counterpart making the observed results solid. 
Moreover, TCGA cases are from an American mixed 
population. It is known that diet and other lifestyle 
risk factors may modify global and gene-specific DNA 
methylation [31–33]. There is evidence also of a differ-
ential DNA methylation in various ethnicities and by 
gender which may be connected with differences in the 
dietary habits and in socioeconomic conditions [31–33]. 
Interestingly, the Czech group of cases derives from a 
relatively small country characterized by a homoge-
neous population (all Caucasians) with individuals 
sharing a very similar diet. This is an important issue 
since the observed differential methylation in tumor 
tissues is, therefore, independent from important bias 
such as diet and ethnicity.
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For two CpGs from our panel (cg1588438 and 
cg9383816), located in the TSS200 region of ADHFE1, 
we observed the same methylation pattern previously 
described in CC cancer patients only [15]. ADHFE1 
encodes iron-containing alcohol dehydrogenase, an 
enzyme responsible for the oxidation of 4-hydroxybu-
tyrate in mammals [34]. The hypermethylation of its 
promoter in CRC has been previously reported [15,35,36]. 
Table 2. Gene ontology enrichment of hyper- and hypomethylated CpG sites in the 5′UTR and upstream gene regions.
GO terms Number of genes (%) adj. p-value†
Hypomethylated genes
Cluster 1, enrichment score 11.7:   
– GO:0004930∼G-protein-coupled receptor activity 44 (15) <0.001
– GO:0004888∼transmembrane receptor activity 51 (18) <0.001
– GO:0007186∼G-protein-coupled receptor protein signaling pathway 48 (17) <0.001
Cluster 2, enrichment score 11.1:   
– GO:0004984∼olfactory receptor activity 29 (10) <0.001
– GO:0007606∼sensory perception of chemical stimulus 31 (11) <0.001
– GO:0007608∼sensory perception of smell 29 (10) <0.001
Cluster 3, enrichment score 8.8:   
– GO:0004888∼transmembrane receptor activity 51 (18) <0.001
– GO:0004872∼receptor activity 57 (20) <0.001
– GO:0004871∼signal transducer activity 63 (22) <0.001
– GO:0060089∼molecular transducer activity 63 (22) <0.001
Hypermethylated genes
Cluster 1, enrichment score 37.5:   
– GO:0007275∼multicellular organismal development 279 (33) <0.001
– GO:0048731∼system development 242 (29) <0.001
– GO:0048856∼anatomical structure development 254 (30) <0.001
– GO:0032502∼developmental process 291 (35) <0.001
Cluster 2, enrichment score 28.7:   
– GO:0022008∼neurogenesis 103 (12) <0.001
– GO:0048699∼generation of neurons 95 (11) <0.001
– GO:0030182∼neuron differentiation 83 (10) <0.001
Cluster 3, enrichment score 14.6:   
– GO:0031326∼regulation of cellular biosynthetic process 232 (28) <0.001
– GO:0009889∼regulation of biosynthetic process 233 (28) <0.001
– GO:0019219∼regulation of nucleobase, nucleoside, nucleotide and nucleic 
   acid metabolic process
223 (27) <0.001
– GO:0051171∼regulation of nitrogen compound metabolic process 224 (27) <0.001
– GO:0080090∼regulation of primary metabolic process 243 (29) <0.001
– GO:0031323∼regulation of cellular metabolic process 250 (30) <0.001
– GO:0019222∼regulation of metabolic process 257 (31) <0.001
– GO:0045449∼regulation of transcription 199 (24) <0.001
– GO:0010556∼regulation of macromolecule biosynthetic process 209 (25) <0.001
– GO:0010468∼regulation of gene expression 206 (25) <0.001
– GO:0060255∼regulation of macromolecule metabolic process 224 (27) <0.001
†p-values were adjusted using the Benjamini–Hochberg method.
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Figure 4.  The different DNA methylation profile across the whole gene, covering TSS1500, TSS200, 5′UTR, 1st exon, gene body 
and 3′UTR regions (see facing page). The DNA methylation profile of the genes: (A) ADHFE1; (B) FLI1; (C) ZNF804B; (D) ZNF793; 
(E) ZNF385B; (F) RASSF2 and (G) GPR85. The y-axes show the absolute methylated fraction (β-value) of each CpG site. The x-axes show 
the CpG ID coordinates.
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Additionally, a previous study reported an inverse cor-
relation similar to our study between ADHFE1 meth-
ylation and its expression [36]. Overall, the results on 
ADHFE1 methylation suggest a role of this gene in 
both CC and RC pathogenesis but the mechanism 
involved remains unclear. Kim et al. [37] showed that 
ADHFE1 transcripts exhibit differentiation-dependent 
expression during in vivo brown and white adipogen-
esis. In another study, ADHFE1 was related to bacterial 
γ-hydroxybutyrate dehydrogenase and resulted having a 
conserved NAD-binding site [38].
The methylation of TFPI2 and its loss of expression 
is a frequent event in human cancers [39,40], including 
CRC [35,41]. Recently, DNA methylation differences 
assessed by a targeted DNA microarray in RC tumors 
also identified TFPI2 as a potential methylation bio-
marker in RC [42]. This potential tumor suppressor gene, 
a Kunitz-type serine proteinase inhibitor, protects the 
extracellular matrix of cancer cells from degradation and 
inhibits in vitro colony formation and proliferation [43]. A 
loss of the TFPI2 function could predispose cells toward 
a proinvasive program, consistent with an important role 
of this protein in later stages of carcinogenesis. TFPI2 
belongs to the group of embryonic cell Polycomb group 
(PcG)-marked genes which participate in the 3D struc-
ture of nuclear DNA [44] and may target genes with a 
characteristic ‘bivalent’ promoter chromatin structure 
containing both active and repressive histone modifica-
tions. Such PcG-marked genes may be predisposed to 
methylation [45] and may thus be good targets for investi-
gation as early diagnostic biomarkers. This phenomenon 
was confirmed by Glockner et al. [45] by the detection of 
TFPI2 methylation in stool DNA.
Concerning FLI1, an inverse correlation between 
the hypermethylation and gene expression was pre-
viously observed [36]. This gene has also been found 
hypermethylated in CRC [46,47]. The FLI1 gene is a 
transcriptional activator playing a role in gene expres-
sion regulation, which is also expected to be important 
in cancer development. All these data were from CRC 
studies and the similarity with our present results may 
indicate that RC and CC share common features in 
their pathogenesis. Interestingly, this particular gene 
resulted as strongly hypermethylated as well as in our 
previous study on HER2+ breast cancer [14].
A majority of the differentially methylated genes 
identified by us were not known to be CRC or RC 
related. These included several genes with large dif-
ferences in β-values: PRKAR1B, TRBJ2-6, HOXA2, 
NKX2-2, PCDH8, TLX1 and MIR129-2. Interest-
ingly, almost all of them presented altered methyla-
tion profiles in several cancers, therefore their func-
tional role in RC should be the subject of further 
research.
Aberrant methylation of the HOXA2 gene was 
recently observed in patients with non-small-cell lung 
carcinoma [48], nasopharyngeal carcinoma [49] and 
malignant and benign biliary tissues [50]. For NKX2-2, 
a hypomethylation was observed in glioblastoma multi-
forme [51] and in breast cancer [52] but not in our previous 
study [14] where we instead found NKX2-4 and NKX2-6 
to be hypermethylated. PCDH8 methylation is a frequent 
event in clear cell renal cell carcinoma [53], bladder [54], 
breast [14] and gastric cancers [55]. Tommasi et al. [56] and 
Lindqvist et al. [14] found a hypermethylated TLX1 in 
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tumor suppressive miRNA frequently methylated in lym-
phoid but not myeloid malignancies, leads to its reversible 
silencing [57]. Recently, a strong hypermethylation was 
observed in HER2+ breast cancer [14].
For the other genes identified in the present study 
(FOXD2, GPR85, GPR88, CHST2, NEUROG3, 
DEF118, DEF118, DEF122, EIF3IP1, BEYLA, BPIL3, 
HBB1, ASCC2, IL22RA2, CAPSLB and HPR1B) no 
data regarding methylation and cancer were available, 
and further cell biological studies of their functional 
roles could be potentially rewarding.
Crossvalidation against TCGA methylation dataset 
showed the reliability and reproducibility of the meth-
ylation differences identified in our array study and 
confirmed the high discriminative and noncoincidental 
potential of the selected biomarkers.
Table 3. Ten most statistically significantly hypo- or hypermethylated CpG sites and genes according to the β-value 
identified in this study.
Gene name Present study TCGA data Chr CpG ID (Location)
Mean β-value Mean β-value
adj. 
p-value




Δβ RC Normal 
mucosa
Hypomethylated CpG sites
MAP3K5 2.1 × 10-15 -0.53 0.19 0.72 1.4 × 10-16 -0.45 0.25 0.70 6 7,474,842Gene body
ITGBL1 3.2 × 10-14 -0.51 0.24 0.73 2.3 × 10-14 -0.50 0.16 0.66 13 11,838,152Gene body
MYBPC3 7.5 × 10-12 -0.50 0.46 0.96 2.5 × 10-67 -0.64 0.32 0.98 11 14,642,259Gene body
adj. to TRBVB 2.2 × 10-13 -0.48 0.30 0.78 1.8 × 10-35 -0.42 0.23 0.65 7 1,703,205
MAP2K2 1.7 × 10-13 -0.48 0.31 0.79 6.5 × 10-22 -0.53 0.21 0.74 19 14,573,876Gene body
adj. to Mafb 2.9 × 10-15 -0.48 0.15 0.64 6.2 × 10-11 -0.47 0.12 0.59 16 3,498,081
adj. to ILα 5.1 × 10-14 -0.48 0.36 0.84 5.1 × 10-10 -0.56 0.24 0.80 2 9,841,889
HPVC1 2.4 × 10-15 -0.48 0.33 0.81 1.3 × 10-13 -0.49 0.24 0.73 7 23,860,325TSS1500
MAP3K5 2.9 × 10-13 -0.48 0.39 0.87 NA NA NA NA 6 26,680,608Gene body
SPAG4L 1.4 × 10-11 -0.47 0.33 0.80 3.1 × 10-35 -0.59 0.29 0.88 20 2,510,8021st Exon, 5′UTR
CYP27A1 3.4 × 10-13 -0.47 0.24 0.71      2,930,667Gene Body
Hypermethylated CpG sites
ADHFE1 9.6 × 10-16 0.62 0.81 0.19 1.2 × 10-16 0.66 0.75 0.09 8 1,588,438TSS200
TFPI2 8.8 × 10-16 0.60 0.75 0.15 NA NA NA NA 7 16,934,178TSS200
ADHFE1 1.9 × 10-13 0.60 0.79 0.19 8.8 × 10-38 0.68 0.72 0.04 8 20,912,1695′UTR, 1st, 
Exon
PRKAR1B 9.6 × 10-14 0.59 0.83 0.23 NA NA NA NA 7 18,601,1675′UTR, TSS200
TRBJ2–6 3.7 × 10-12 0.59 0.82 0.23 2.4 × 10-09 0.61 0.64 0.13 7 9,493,063CpG Island
PRKAR1B 7.3 × 10-14 0.58 0.80 0.27 NA NA NA NA 7 13,895,2355′UTR, TSS200
adj. to SOX-1 8.4 × 10-12 0.57 0.76 0.18 3.7 × 10-16 0.61 0.69 0.08 13 25,570,913CpG Island
ADHFE1 2.1 × 10-14 0.57 0.72 0.16 1.0 × 10-31 0.62 0.69 0.07 8 9,383,816TSS200
TFPI2 1.2 × 10-14 0.56 0.69 0.13 5.3 × 10-07 0.55 0.70 0.15 7 20,230,721Gene body
FLI1 4.0 × 10-10 0.56 0.74 0.18 2.6 × 10-23 0.63 0.70 0.07 11 11,017,065Gene 
body,5′UTR
NPY 9.9 × 10-14 0.56 0.74 0.21 NA NA NA NA 7 16,964,348 TSS200
OPLAH 1.1 × 10-12 0.56 0.69 0.16 NA NA NA NA 8 17,698,295Gene body
ITGA4 9.9 × 10-14 0.56 0.62 0.09 NA NA NA NA 2 6,952,6715′UTR;1stExon
SND1 7.3 × 10-15 0.55 0.67 0.14 NA NA NA NA 7 9,296,001Gene body
Δβ, delta beta is the value of the differential methylation. Negative Δβ-values reflect hypomethylated status while positive Δβ an hypermethylated one.
The adjusted p-value was considered significant when < 0.05 [27].
adj.: Adjusted; Adj. to: Adjacent to gene from 5′ side; Body: Intragenic CpG sites; CGI: CpG island; CGI shore: Regions 2000 bp away from the CpG island; 
Chr:  Chromosome number; CpG ID (Location): The coordinate of the CpG location according to the human genome build 37; NA: Data missing; RC: Rectal cancer. 
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The majority of differentially methylated CpG sites 
in our study were located in the gene body region. 
Intragenic DNA methylation may also affect the tran-
scription from alternate promoters or the transcrip-
tion of noncoding RNAs [58,59]. CpGs methylation in 
gene exons is a major cause of C to T transition muta-
tions, leading to cancer causing mutations in somatic 
cells [60]. The functional role of intragenic DNA 
methylation needs further validation by expression 
analyses since the available data are conflicting [19]. 
For example, promoter methylation is inversely cor-
related with expression, whereas methylation in the 
gene body is positively correlated with expression [58]. 
Thus, in mammals, it is the initiation of transcrip-
tion but not transcription elongation that seems to be 
sensitive to DNA methylation silencing. This could 
be one of the reasons for lack of any inverse correla-
tion of hypermethylated genes with their expression 
levels. However, the TCGA dataset contained very 
few paired ANMRM samples to go with the tumor 
tissues, which detracts from its usefulness to validate 
methylation/expression correlations.
During early stages of CRC or RC, epigenetic 
alterations appear to exceed the frequency of genetic 
mutations, suggesting their greater potential for the 
next generation of diagnostic biomarkers for the 
detection of increased risk of cancer transformation.
Our data may further contribute in understanding 
the role of aberrant methylation and other molecular 
mechanisms in RC pathogenesis. Collaborative efforts 
will ultimately result in the employment of epigeneti-
cally based approaches to be commonly used to guide 
RC prevention and treatment. Limiting a study to a 
well-defined anatomical location such as the RC may 
reduce the noise levels in the array data studies and 
thereby increase the rate of successful identification 
of novel epigenetic biomarkers.
In conclusion, our large and sufficiently powered 
clinical study with independent external validation 
has demonstrated the feasibility of using specific 
methylated DNA signatures for developing putative 
diagnostic biomarkers in RC.
Future perspective
Our data contribute to improved understanding of 
the role of gene-specific aberrant methylation in rec-
tal cancer pathogenesis. Treating rectal cancer as an 
independent entity may improve discovery of bio-
markers used for early detection and prognosis. In 
the future, new biomarker genes will be established 
and their association with patients’ survival will be 
addressed. The current study contributes to the estab-
lishment of such new biomarkers, with the identifica-
tion of BPIL3, HBBP1, TIFPI2, ADHFE1, FLI1 and 
TLX1 genes.
Supplementary data
To view the supplementary data that accompany this paper 
please visit the journal website at: www.futuremedicine.
com/doi/full/10.2217/epi-2016-0044
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Executive summary
•	 Rectal cancer (RC) comprises about a third of all colorectal cancer cases and the location of RC makes it 
difficult to perform operative resection; therefore irradiation is used as an alternative treatment.
•	 The DNA methylation profile of 32 pairs of RC and adjacent nonmalignant rectal mucosa’s showed that 
majority of the CpG sites are hypermethylated in RC.
•	 The BPIL3 and HBBP1 genes were hypomethylated in rectal cancer, whereas TIFPI2, ADHFE1, FLI1 and TLX1 
genes were hypermethylated.
•	 Cross-validation against TCGA methylation dataset showed the reliability and reproducibility of the 
methylation differences identified in our array study and confirmed the high discriminative and 
noncoincidental potential of the selected biomarkers.
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Supplementary Figure 1. Differential DNA methylation (tumour vs. ANMRM) across chromosomes. Blue bars show hypermethylation and the 
red bars hypomethylation. Rectal pairs 5, 11, 12, 18 and 29 were removed from further analysis due to complete lack of methylation differences. 
 
 
Supplementary Figure 2. Genes validated with Pyrosequencing assay technology using the adjacent non-malignant rectal mucosa (ANMRM, n 





















Supplementary Figure 3. Expression levels of TLX1 gene from TCGA dataset (https://tcga-data.nci.nih.gov/tcga/) 
 
Supplementary Table S1. Genes validated with Pyrosequencing assay technology.  
The amplicon size, annealing temperature and Mg2+ concentration are shown for each PCR 
primer pair. The sequence to analyze and the target CpG site is underlined and colored red.   
Gene 
CpG site ID 









Fw GGGGTTTATGGTGTAGGG 229 54 2.5 
 Rev-biotin TCCTCTCCCTCTTACACAATT    
 Seq primer AGGTTTTTTGTTTTAGG    





   





210 56 1.5 
 Rev-biotin ATCCTTTTCAATTATAACTTATTCCT
ATTTATCA  
   
 Seq primer GTGTGTAGTTTATTTTTTAAGGA     




   





142 54 2.0 
 Rev-biotin AACTCAAAACCATTTTCCCAC     
 Seq primer GGTAATTTTAAGGGTGGA     




   
      
BPIL3 
cg25345102  
Fw AGGGGGTTTAATTTGTTTTGAGA  139 56 2.0 
 Rev-biotin ACCAATCAACAAACTACAAAATACC     
 Seq primer TAGGGTTTGGTGGGT     




   
      
FLI1 
cg27028555  
Fw GTTAGTTTTTTGGGGATTAGGAAG  117 56 2.0 
 Rev-biotin CCCTAAACCACCTATCC     
 Seq primer TGTTTGGGAGTTAGTG     
 Seq to 
analyze 
T TTGGGTYGTY GGGTTYGGGT 
AAGYGTTGGG 
   
TLX1 
cg25741023  
Fw-biotin GTATAGTTAATGGAGAGATTTAGT  138 54 2.0 
 Rev TATTCTTCCCCTCTCTAACTTCTACT
T  
   
 Seq primer ATACAAAAAAACTTC     




   
Supplementary Table S2. Comparison of the CpG sites identified in our study by the unguided hierarchical clustering analysis and from the 
TCGA database (https://tcga-data.nci.nih.gov/tcga/). The order of genes is reflected with the respect to those shown by heatmap. 
Gene name 
Present study  TCGA database  
Chr CpG ID (Location) 
Mean β-value Mean β-value 
adj. p Δβ RC  Normal mucosa adj. p Δβ RC Normal mucosa 
C1orf77 4.1e-10 0.32 0.74 0.42 5.4e-6 0.34 0.71 0.37 1 2482497 Gene body 
HOXA2 4.7e-9 0.39 0.83 0.44 2.5e-6 0.53 0.84 0.31 7 2803819 Gene body 
FOXD2 3.3e-7 0.29 0.65 0.36 2.5e-23 0.34 0.65 0.31 1 3440588TSS1500 
NKX2-2 2.7e-7 0.41 0.59 0.17 2.5e-29 0.50 0.56 0.06 20 22474464 Gene body 
MIR34B 2.9e-8 0.45 0.55 0.10 2.1e-36 0.54 0.59 0.04 11 22879515TSS200 
GPR88 1.8e-6 0.16 0.94 0.77 2.5e-5 0.29 0.90 0.61 5 18421360 Gene body 
TFPI2 2.1e-14 0.50 0.58 0.08 2.8e-15 0.52 0.61 0.09 7 12973591 Gene body 
PCDH8 1.2e-8 0.35 0.55 0.21 2.2e-25 0.39 0.49 0.10 13 2873121st Exon 
TLX1 5.2e-10 0.39 0.48 0.09 2.5e-37 0.45 0.54 0.09 10 299972 Gene body 
CHST2 6.3e-12 0.43 0.67 0.23 4.8e-6 0.51 0.69 0.18 3 17373442 Gene body 
MSC 5.3e-12 0.44 0.60 0.16 2.2e-9 0.31 0.59 0.18 8 6269753 Gene body 
LOC283922 0.30 0.004 0.05 0.05 2.7e-3 0.01 0.09 0.08 16 27401698 Gene body 
C17orf46 1.3e-9 0.51 0.60 0.09 3.4e-41 0.55 0.58 0.03 17 4992638 Gene body 
EID3 1.8e-5 0.25 0.54 0.29 NA NA NA NA 12 50577771st Exon 
MIR129-2 8.1e-9 0.47 0.70 0.24 8.5e-6 0.42 0.59 0.17 11 1939477TSS200 
NEUROG3 2.6e-6 0.30 0.46 0.16 4.8e-13 0.30 0.47 0.17 10 12938159 Gene body 
RASSF2 3.2e-7 -0.34 0.55 0.89 9.9e-25 -0.38 0.45 0.83 20 14750543 Gene body 
GPR85 4.6e-10 -0.37 0.47 0.84 2.6e-34 -0.49 0.35 0.84 7 14511782 Gene body 
LOC283914 2.3e-11 -0.35 0.46 0.81 NA NA NA NA 16 269291631 Gene body 
DEFB119 2.5e-10 -0.34 0.43 0.77 7.9e-41 -0.39 0.32 0.71 20 18462653 Gene body 
C20orf197 2.3e-12 -0.27 0.47 0.75 2.1e-15 -0.31 0.41 0.72 20 9076077 TSS1500 
EIF3IP1 1.1e-10 -0.34 0.43 0.77 1.4e-41 -0.51 0.35 0.86 7 14146669 Gene body 
DEFB118 4.1e-9 -0.37 0.51 0.88 2.7e-28 -0.46 0.39 0.85 20 20312687 Gene body 
DEFB122 4.4e-10 -0.33 0.46 0.79 2.0e-10 -0.46 0.32 0.78 20 1349088 Gene body 
BEYLA 2.2e-9 -0.32 0.41 0.74 NA NA NA NA 8 12866122 Gene body 
LOC339568 5.4e-9 -0.35 0.37 0.72 3.0e-13 -0.52 0.22 0.74 20 4742334 Gene body 
BPIL3 1.1e-8 -0.35 0.48 0.83 3.4e-18 -0.44 0.30 0.74 20 1822339 Gene body 
HBBP1 1.0e-8 -0.30 0.59 0.90 1.7e-32 -0.44 0.40 0.84 11 4161236 Gene body 
SAMSN1 6.5e-12 -0.36 0.38 0.73 7.8e-15 -0.48 0.25 0.73 21 13951664 Gene body 
ASCC2 2.7e-9 -0.31 0.37 0.68 8.4e-34 -0.35 0.31 0.66 22 147442445 Gene body 
IL22RA2 5.8e-8 -0.30 0.40 0.71 1.3e-25 -0.35 0.32 0.67 6 23507945 Gene body 
CAPSL 2.8e-9 -0.30 0.54 0.84 1.9e-29 -0.39 0.45 0.84 5 10842703´UTR 
BMPR1B 4.9e-8 -0.32 0.46 0.90 NA NA NA NA 4 188366615´UTR 
Negative Δβ-values reflect an hypomethylated status while  positive Δβ an hypermethylated on RC, rectal cancer; Δβ, delta beta is the value of 
the differential methylation; Chr, Chromosome number; CpG ID (Location), the coordinate of the CpG location according to the human genome 
build 37; CGI, CpG island; CGI shore, regions 2000 bp away from the CpG island; Body, intragenic CpG sites; NA, data missing. The adjusted 
p-value was considered significant when < 0.05. 
 
